<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EEA90A41-FE78-4648-A169-978B7D07858E"><gtr:id>EEA90A41-FE78-4648-A169-978B7D07858E</gtr:id><gtr:firstName>Assan</gtr:firstName><gtr:surname>Jaye</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190092702"><gtr:id>2454336F-B0C3-4AFC-8105-100DC3828A61</gtr:id><gtr:title>A study of four markers of immune activation and disease progression: a comparison between HIV-1 and HIV-2 infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190092702</gtr:grantReference><gtr:abstractText>Infection with the HIV germ (virus) that causes AIDS is accompanied with massive activation of the bodys defence system. When this activation happens over a long time it causes exhaustion of all the defence systems of the body. This germ causes massive death to the cells that defend the body against infections (CD4) through this intense activation. The measurement of the levels of soluble chemicals that arise from this activation has been shown to be easy to perform and may be better predictor of the progression of disease in HIV infection to AIDS status than the conventional CD4 counts and measurement of the levels of virus circulating in the blood. This study therefore aims to measure and compare four soluble chemicals in the body that indicate the levels of chronic activation of the defence system in HIV-1 and HIV-2 infected subjects. These chemicals are named as: neopterin, beta 2-microglobulin, lipolysaccharide and suPAR all of which have been shown to be increased in HIV infected compared to uninfected individuals. This comparison will make us understand better the role of intense activation in making HIV-infected patients to deteriorate during the course of their illness.</gtr:abstractText><gtr:technicalSummary>There is still insufficient explanation as to how HIV causes profound loss of CD4 T cells, despite only a small proportion of cells being infected. Recent reports suggest a massive loss of CD4 from the gut early in infection which has been attributed largely to immune activation. Chronic immune activation, which is a hallmark of HIV infection, is therefore thought to partly account for the CD4 T cell depletion and immune dysfunction. Indeed, immune activation has been suggested as a stronger predictive factor for disease progression in HIV than the conventional CD4 counts and viral load. The soluble immune activation biomarkers neopterin, beta 2-microglobulin (beta 2-M), lipopolysaccharide (LPS) and soluble urokinase plasminogen activator receptor (suPAR) have all been shown to be upregulated in HIV compared to uninfected individuals. The levels are significantly higher in advanced cases (symptomatic phase) than early in the course of infection (asymptomatic phase). This study proposes to evaluate in a head to head comparison the levels of immune activation markers using retrospective stored plasma samples from HIV-1 and HIV-2 positive individuals in the Fajara HIV Cohort. A comprehensive evaluation of immune activation markers in disease progressing and non-progressing individuals will provide clues as to how HIV causes disease.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-07-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>168098</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Research Trust, UK (www.hivresearchtrust.org.uk)</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>HIV Research Trust</gtr:fundingOrg><gtr:id>C04B8E37-9B03-4AAC-9094-2824C1A9BEC7</gtr:id><gtr:outcomeId>n76bT2UqJku0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Research Trust-UK ( www.hivresearchtrust.org.uk)</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>HIV Research Trust</gtr:fundingOrg><gtr:id>DE3943DC-3084-4110-B01E-9AB20FC719E0</gtr:id><gtr:outcomeId>FGdJudLrsnk0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2E5BDA36-AAF4-46A4-B674-216E665F0587</gtr:id><gtr:title>Downregulation of the T-cell receptor by human immunodeficiency virus type 2 Nef does not protect against disease progression.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/454abd45acde87969c2971d70129f029"><gtr:id>454abd45acde87969c2971d70129f029</gtr:id><gtr:otherNames>Feldmann J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>qBS98ZUYooS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E49746E-DF9D-4A38-8770-02DB795080F3</gtr:id><gtr:title>Use of Self-Reported Adherence and Keeping Clinic Appointments as Predictors of Viremia in Routine HIV Care in the Gambia.</gtr:title><gtr:parentPublicationTitle>Journal of the International Association of Providers of AIDS Care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c306d45a1a18041c07012c2e6ffbf28"><gtr:id>8c306d45a1a18041c07012c2e6ffbf28</gtr:id><gtr:otherNames>Peterson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2325-9574</gtr:issn><gtr:outcomeId>546257d3a09be9.80943428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F95D090-F31B-45D4-858D-CF7C101DA1C6</gtr:id><gtr:title>Are plasma biomarkers of immune activation predictive of HIV progression: a longitudinal comparison and analyses in HIV-1 and HIV-2 infections?</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d4bec89b63675f4ca163786a7f26441"><gtr:id>7d4bec89b63675f4ca163786a7f26441</gtr:id><gtr:otherNames>Nyamweya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15883_23_22970212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04EE4DFE-879E-4B2C-8E68-9CDB2856BC81</gtr:id><gtr:title>Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis.</gtr:title><gtr:parentPublicationTitle>Reviews in medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d4bec89b63675f4ca163786a7f26441"><gtr:id>7d4bec89b63675f4ca163786a7f26441</gtr:id><gtr:otherNames>Nyamweya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1052-9276</gtr:issn><gtr:outcomeId>pm_15883_23_23444290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7287348D-2F21-405F-8EA6-80F5C9128B09</gtr:id><gtr:title>Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5084887305d0865f5da773ae0e86097"><gtr:id>e5084887305d0865f5da773ae0e86097</gtr:id><gtr:otherNames>Togun T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>KwcdELqHhun</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9E3CCE9-46A9-413B-924F-D1F6C59F62C5</gtr:id><gtr:title>Direct relationship between virus load and systemic immune activation in HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0ae9c03e19152fa146debeb3e0a9814"><gtr:id>c0ae9c03e19152fa146debeb3e0a9814</gtr:id><gtr:otherNames>Leligdowicz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>LsgW51mn5Ce</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97E05ECB-255B-40B5-9AC8-8D4AE2313379</gtr:id><gtr:title>CD4 intragenic SNPs associate with HIV-2 plasma viral load and CD4 count in a community-based study from Guinea-Bissau, West Africa.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b57f3faab5ebc7c5cb4b1e9f15656da1"><gtr:id>b57f3faab5ebc7c5cb4b1e9f15656da1</gtr:id><gtr:otherNames>Hennig BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_15883_23_20924289</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190092702</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>